Chemokines and the pathophysiology of neuropathic pain
Top Cited Papers
- 18 December 2007
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 104 (51) , 20151-20158
- https://doi.org/10.1073/pnas.0709250104
Abstract
Chemokines and chemokine receptors are widely expressed by cells of the immune and nervous systems. This review focuses on our current knowledge concerning the role of chemokines in the pathophysiology of chronic pain syndromes. Injury- or disease-induced changes in the expression of diverse chemokines and their receptors have been demonstrated in the neural and nonneural elements of pain pathways. Under these circumstances, chemokines have been shown to modulate the electrical activity of neurons by multiple regulatory pathways including increases in neurotransmitter release through Ca-dependent mechanisms and transactivation of transient receptor channels. Either of these mechanisms alone, or in combination, may contribute to sustained excitability of primary afferent and secondary neurons within spinal pain pathways. Another manner in which chemokines may influence sustained neuronal excitability may be their ability to function as excitatory neurotransmitters within the peripheral and central nervous system. As is the case for traditional neurotransmitters, injury-induced up-regulated chemokines are found within synaptic vesicles. Chemokines released after depolarization of the cell membrane can then act on other chemokine receptor-bearing neurons, glia, or immune cells. Because up-regulation of chemokines and their receptors may be one of the mechanisms that directly or indirectly contribute to the development and maintenance of chronic pain, these molecules may then represent novel targets for therapeutic intervention in chronic pain states.Keywords
This publication has 102 references indexed in Scilit:
- Homologous and heterologous desensitization of capsaicin and mustard oil responses utilize different cellular pathways in nociceptorsPAIN®, 2008
- 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1Proceedings of the National Academy of Sciences, 2007
- Inhibition of spinal microglial cathepsin S for the reversal of neuropathic painProceedings of the National Academy of Sciences, 2007
- ASIC3 in muscle mediates mechanical, but not heat, hyperalgesia associated with muscle inflammationPain, 2007
- Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in ratsDrug and Alcohol Dependence, 2007
- CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathyBrain, Behavior, and Immunity, 2007
- Glia as the “bad guys”: Implications for improving clinical pain control and the clinical utility of opioidsBrain, Behavior, and Immunity, 2006
- Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkineBrain, Behavior, and Immunity, 2006
- Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal gangliaNeuroscience, 2006
- The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tractNature, 1998